However, it was demonstrated that the concentrations of recombinant IFNα2 used (5–10×106 U/m2, three times a week) lead to an intolerable toxicity in patients with advanced prostate carcinoma (Chang et al. 1986). This evidence concerns the gene IFNA2 and prostate carcinoma.